LACTIN-V Study for Recurrent Bacterial Vaginosis

PHASE2CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

June 3, 2016

Primary Completion Date

February 11, 2019

Study Completion Date

February 11, 2019

Conditions
Bacterial Vaginosis
Interventions
BIOLOGICAL

Lactobacillus crispatus CTV-05

LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10\^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.

DRUG

Metronidazole

Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days

OTHER

Placebo

Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.

Trial Locations (4)

60612

Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago

63110

Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit, St Louis

92103-8208

University of California, San Diego - Antiviral Research Center, San Diego

94110-3518

San Francisco General Hospital - Infectious Diseases, San Francisco

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02766023 - LACTIN-V Study for Recurrent Bacterial Vaginosis | Biotech Hunter | Biotech Hunter